

ABRAXANE AGREEMENT REMINDER

Oncology Associates would like to remind you of its agreement for Abraxane (Paclitaxel protein-bound particles for injectable suspension) with Abraxis Oncology. The agreement will run until March 22, 2007 and the product is available in 100 mg vials.



Abraxane for Injectable Suspension is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

NEUMEGA AGREEMENT REMINDER

Oncology Associates would like to remind you of its agreement with Wyeth Pharmaceuticals for purchases of Neumega (oprelvekin). The agreement offers a floating 5% discount to all OA Members and is effective March 1, 2006 for a period of one year.



NDC #	Vial Size	Vials/Box	% Off List
58394-004-01	5 mg	1 vial; 1x10	Float 5%
58394-004-02	5 mg	1 x 7	Float 5%

IN OTHER NEWS

ABRAXIS LAUNCHES NEW ABRAXANE PATIENT ASSISTANCE PROGRAM Comprehensive Program Provides Access to Care for Cancer Patients

Abraxis BioScience announced the launch of the Abraxis Patient Access Program (APAP), a comprehensive patient assistance program for cancer patients being treated with ABRAXANE* (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Through APAP, financially eligible cancer patients in need of treatment with ABRAXANE will receive access to the drug at no cost. This new program, which replaces the previous ABRAXANE patient assistance programs, makes it possible for financially eligible cancer patients to receive assistance in all instances where ABRAXANE has been prescribed.

"Through our new patient assistance program, we will be able to provide eligible cancer patients with ABRAXANE at no cost," said Patrick Soon-Shiong, Chairman and Chief Executive Officer of Abraxis BioScience. We are committed to ensuring there are no cost barriers for cancer patients who may benefit from treatment with ABRAXANE."

Access to this program is available through the Abraxis Resource Center (ARC of Support), a comprehensive program that provides a broad range of services caring for patients being treated with ABRAXANE. This new program offers two distinct access points for cancer patients:

- > ABRAXANE at no cost to eligible uninsured patients with a household adjusted gross income of less than \$75,000 per year.
- > Replacement of ABRAXANE at no cost for physicians treating an eligible insured patient, who requires additional financial support following a denied insurance claim.

Physicians who wish to enroll a patient in the program should call the **ARC of Support** at **1-800-564-0216**, option three. For more information about ABRAXANE and the services provided by ARC of Support including APAP, please visit www.abraxane.com.

NEW DIAGNOSIS CODES: Effective October 1, 2006

A link to these codes can be found on OA's website at www.oagpo.com under News and Events on the homepage.

NEW DACOGEN J CODE: J0894

Effective January 1, 2007, CMS has assigned **J0894** as the specific Healthcare Common Procedure Coding System (HCPCS) J code for DACOGEN (decitabine) for Injection to be used with third party payers in the physician office and hospital settings. The billing unit for this code is 1 mg. DACOGEN is supplied in a 50 mg single-dose vial. Visit www.dacogen.com for full prescribing information.